Medical Journals

Aminoglycoside-induced Ototoxicity.

Authors:
  • Selimoglu Erol

From: Inonu University, Department of Otorhinolaryngology, Malatya, Turkey. erolselimoglu@hotmail.com

Current pharmaceutical design

  • Publish Date: 2007
  • ISSN: 1873-4286
  • Volume: 13
  • Issue: 1
  • Pages: 119-26
  • Medium: Internet
  • Language: English
  • Citation (JAMA): Selimoglu Erol, et al. Aminoglycoside-induced Ototoxicity.. Curr. Pharm. Des. 2007;13:119-26

Abstract

It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity. Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamicin are primarily cochleotoxic. Cochlear damage can produce permanent hearing loss, and damage to the vestibular apparatus results in dizziness, ataxia, and/or nystagmus. Aminoglycosides appear to generate free radicals within the inner ear, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss. Two mutations in the mitochondrial 12S ribosomal RNA gene have been previously reported to predispose carriers to aminoglycoside-induced ototoxicity. As aminoglycosides are indispensable agents both in the treatment of infections and Meniere’s disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity. Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides. In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.

Mesh Headings (Keywords): Aminoglycosides, Animals, Anti-Bacterial Agents, Cochlea, Dose-Response Relationship, Drug, Drug Administration Schedule, Genetic Predisposition to Disease, Genetic Screening, Hair Cells, Auditory, Hearing Disorders, Humans, Incidence, Meniere Disease, Mutation, RNA, RNA, Ribosomal, Risk Assessment, Risk Factors, Vestibule, Labyrinth


Check for Full Text / PubMed Unique Identifier (PMID): 17266591


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.